Immune Thrombocytopenia (ITP) Market Size was valued at USD 3.5 Billion in 2022. The Immune Thrombocytopenia (ITP) market industry is projected to grow from USD 3.54 Billion in 2023 to USD 3.93 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 1.30% during the forecast period (2023 - 2032). Rising frequency of target illnesses, unmet requirements of Immune thrombocytopenia patients driving medication development, and growing R&D are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for immune thrombocytopenia (ITP) is being driven by the rising prevalence of immune thrombocytopenic. The rising prevalence of immune thrombocytopenic purpura in many parts of the world is expected to increase the need for therapy. Increasing acute and chronic immune thrombocytopenia occurrences are expected to promote therapeutic treatment acceptability globally throughout the predicted period. Increasing patient and healthcare professional knowledge regarding healthcare and uncommon illnesses in emerging nations is expected to fuel immune thrombocytopenia market growth during the study period. Non-governmental organizations such as the Platelet Disorder Support Association and the Immune Thrombocytopenia Support Associations actively alert the public about uncommon blood illnesses such as ITP. These non-government activities are expected to boost the market's therapeutic demand for immune thrombocytopenia medications.
"Tertiary and secondary lines of treatment are expensive, imposing a significant financial burden on affected patients suffering from immune thrombocytopenia and their family members." Government agencies and commercial companies are working to increase patient access and control medicine pricing for treating idiopathic thrombocytopenic purpura. Rising funding assistance from the government and private sector is expected to propel the immune thrombocytopenia market expansion. Healthcare reimbursement policies in European nations such as Germany and France are patient-centered. Approximately 80% of European nations provide free public health care. In addition, support organizations such as the ITP Support Association help patients ease financial burdens through donations and financial assistance.
The only therapy choices for decades were splenectomy and corticosteroids, followed by plasma-derived therapies. However, a broader therapy repertoire for ITP illness is emerging as biology advances. Many firms are investing in research and development to bring a new medication for ITP to market. Currently, research and development efforts are mostly focused on integrating medicines to address various disease pathways simultaneously. There are several first-line therapeutic options for idiopathic thrombocytopenic purpura (ITP). However, there are times when first-line therapy fails to produce satisfactory outcomes. Other medicines, such as second and third-line therapies, are necessary to treat the condition. These medicines aid in the control of platelets, the prevention of bleeding, the reduction of tiredness, and the improvement of health-related quality of life (HRQoL), all of which are key unmet requirements in ITP. As a result, increased demand for second and third-line medicines propels market expansion. Thus, driving the Immune Thrombocytopenia (ITP) market revenue.
Based on treatment, the Immune Thrombocytopenia (ITP) market segmentation includes intravenous immunoglobulins, corticosteroids, thrombopoietin receptor agonists, and others. The corticosteroids segment dominated the market, accounting for 35% of market revenue. This is mostly due to the increased use of intravenous immunoglobulins for treating and managing immunological thrombocytopenia. Furthermore, the patent expiration of important TPO-RA branded medications is expected to lower the cost of second-line therapy, reducing the drug class's market value.
Based on end users, the Immune Thrombocytopenia (ITP) market segmentation includes hospitals and clinics, specialty centers, research and academic institutes, and others. The hospitals and clinics generated the most income because of the increased use of intravenous ITP treatments such as immunoglobulins and TPO-RA. Furthermore, greater rates of bleeding issues in people with immune thrombocytopenia lead to an increase in the use of rescue therapy in hospitals. This element also helps hospital pharmacies lead the ITP market.
Figure 1: Immune Thrombocytopenia (ITP) Market, by End user, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Immune Thrombocytopenia (ITP) market area will dominate this market, Higher access to ITP therapy, the increased presence of major market players, enhanced healthcare infrastructure, and growing awareness of uncommon blood disorders are projected to affect the immune thrombocytopenia market in North America favorably.
Further, the major countries studied in the market report are The US, Canada, German, Italy, Spain, China, Japan, India, France, the UK, Australia, South Korea, and Brazil.
Figure 2: IMMUNE THROMBOCYTOPENIA (ITP) MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has the second-largest market share for Immune Thrombocytopenia (ITP) owing to rising financial and monetary assistance from non-government and government organizations towards ITP sufferers. Furthermore, the German Immune Thrombocytopenia (ITP) market dominated, while the UK Immune Thrombocytopenia (ITP) market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Immune Thrombocytopenia (ITP) Market will develop at the quickest CAGR. Due to increased R&D focus on uncommon disorders such as immune thrombocytopenia. Furthermore, China's Immune Thrombocytopenia (ITP) market had the highest market share, whereas India's Immune Thrombocytopenia (ITP) market was the Asia-Pacific region's fastest growing.
Immune Thrombocytopenia (ITP) Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Immune Thrombocytopenia (ITP) market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Immune Thrombocytopenia (ITP) industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Immune Thrombocytopenia (ITP) industry to serve clients and expand the market sector. The Immune Thrombocytopenia (ITP) industry has provided some of the most important benefits recently. Intas, and other major companies in the Immune Thrombocytopenia (ITP) market are aiming to enhance market demand by investing in research and development activities.
Intas is a biosimilars pioneer, having developed and commercialized the most indigenous biosimilars in India. The firm has a long history of making high-quality biosimilars available to the general public. Intas drugs such as Neukine (Filgrastim), Mabtas (Rituximab), Pegasta (Pegfilgrastim), Razumab (Ranibizumab), Bevatas (Bevacizumab), and Eleftha (Trastuzumab) have revolutionized the management of their respective therapies due to their low cost. Romy is the latest example of Intas' 'Biosimilar for Billions' philosophy, demonstrating the company's dedication to providing superior cancer care to the masses. Biosimilars from Intas are produced in the company's cutting-edge European Union - Good Manufacturing Practises (EU-GMP) accredited biotechnology facilities near Ahmedabad, Gujarat. In June 2019, Intas Pharmaceuticals makes chronic immune thrombocytopenia (ITP) medication more accessible to patients by being the first to offer Romiplostim in India under the brand name Romy. Romiplostim is a very effective medication with long-term advantages in chronic ITP.
Fostamatinib is also being explored in an NIH/NHLBI-sponsored Phase 3 clinical research to treat COVID-19 in hospitalized patients (NCT04924660). Two of their other clinical programs are an interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK) inhibitor program. Rigel and Eli Lilly are working to develop RIPK1 inhibitors for immunological and neurological illnesses. Rigel also has a large portfolio of investigational agents under development with our other partners. These medicines target specific signaling pathways, such as Axl tyrosine kinase (AXL) and murine double minute 2 (MDM2). They can benefit from extra knowledge and resources and the potential success of these future goods through strategic partnerships and collaborations. In annuary 2020, TAVLESSE has been launched in Europe by Rigel Pharmaceuticals, Inc., in collaboration with Grifols S.A. The product was first introduced in Germany and the United Kingdom. In January 2020, the European Commission authorized it to treat persistent immune thrombocytopenia in adult patients who have failed conventional therapies.
Key Companies in the Immune Thrombocytopenia (ITP) market include
Amgen Inc.
F.Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd
Rigel Pharmaceuticals, Inc.
Shionogi Inc.
Dova Pharmaceuticals
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Shire
Ligand Pharmaceuticals, Inc.
Immune Thrombocytopenia (ITP) Industry Developments
May 2022: argenx SE reported encouraging results from the VYVGART® (efgartigimod alfa-fcab) Phase 3 ADVANCE study. In individuals suffering from primary ITP. ADVANCE accomplished its main goal, indicating that a greater proportion of chronic ITP patients receiving VYVGART saw a sustained platelet count response compared to placebo. The first Phase 3 clinical study of a neonatal Fc receptor (FcRn) blocker in ITP is ADVANCE.
December 2022: Argenx's victory over immune thrombocytopenia demonstrates that efgartigimod is not a one-trick pony in autoimmune illness. As efgartigimod gets momentum in myasthenia gravis, argenx is trying to demonstrate that its antibody fragment is not a one-hit-wonder. With a phase 3 victory in primary immune thrombocytopenia (ITP), the firm supports its argument that the neonatal-receptor-binding medication may reduce antibodies involved in various autoimmune disorders.
June 2020: In collaboration with The ITP Support Association, Novartis is excited to introduce the ITP Pocket Log, which is meant to help patients manage their ITP on the go, document symptoms, and have more productive conversations with their doctor. Keeping track of symptoms for patients with immune thrombocytopenia (ITP) can be difficult, but alerting their doctor about them is critical. People can use the ITP pocket journal to note symptoms and grade their severity. It also allows patients to save additional relevant information such as blood test results (platelet count), drugs they are taking, and critical contact information in one convenient location.
Intravenous immunoglobulins
Corticosteroids
Thrombopoietin receptor agonists
Others
Hospitals and clinics
Specialty Centers
Research and Academic Institutes
Others
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 3.5 Billion |
| Market Size 2023 | USD 3.54 Billion |
| Market Size 2032 | USD 3.93 Billion |
| Compound Annual Growth Rate (CAGR) | 1.30% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, End user, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Shionogi Inc., Dova Pharmaceuticals, Novartis AG, Jiangsu Hengrui Pharmaceutical Co., Ltd., Shire and Ligand Pharmaceuticals, Inc. |
| Key Market Opportunities | Rising spending on R & D |
| Key Market Dynamics | Increase in health difficulties and worries, |
Immune Thrombocytopenia (ITP) Market Highlights:
Frequently Asked Questions (FAQ) :
The Immune Thrombocytopenia (ITP) market size was valued at USD 3.5 Billion in 2022.
The market is projected to grow at a CAGR of 1.30% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Shionogi Inc.
The Corticosteroids dominated the market in 2022.
The store based had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
